More about
Drug-Eluting Stent
News
April 20, 2020
1 min read
Save
PRECOMBAT
News
February 24, 2020
2 min read
Save
BIOFLOW V: SES reduces event rates at 3 years vs. EES

Patients who underwent coronary revascularization with a bioresorbable polymer sirolimus-eluting stent had significantly lower rates of target vessel MI, late/very late stent thrombosis and clinically driven target lesion revascularization compared with those who underwent the procedure with a durable polymer everolimus-eluting stent, according to 3-year data from the BIOFLOW V trial presented at Cardiovascular Research Technologies.
News
January 31, 2020
2 min read
Save
Meta-analysis of paclitaxel-coated balloons in CLI ‘should have no meaningful impact’
News
January 09, 2020
2 min read
Save
PCI with ridaforolimus-eluting stent confers similar 2-year outcomes as ZES
News
December 01, 2019
1 min read
Save
Top stories from VIVA: Peripheral DES, drug-coated balloons and more
News
November 14, 2019
3 min read
Save
Bioresorbable scaffold effectively treats below-the-knee lesions
News
November 07, 2019
2 min read
Save
Sirolimus-coated balloon benefit maintained at 2 years
News
November 05, 2019
2 min read
Save
IMPERIAL: Peripheral DES similar in patency, different in TLR at 2 years
News
November 05, 2019
3 min read
Save
Mortality not different at 5 years in patients treated with DES vs. controls
News
October 31, 2019
2 min read
Save